# Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant

> **NCT07075718** · PHASE2,PHASE3 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 610 (estimated)

## Conditions studied

- Glaucoma

## Interventions

- **DRUG:** Gen 2 Travoprost Intracameral Implant
- **DRUG:** Timolol eye drops 0.5%
- **PROCEDURE:** Sham Procedure
- **OTHER:** Placebo eye drops

## Key facts

- **NCT ID:** NCT07075718
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-12
- **Primary completion:** 2028-03
- **Final completion:** 2032-03
- **Target enrollment:** 610 (ESTIMATED)
- **Last updated:** 2026-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07075718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07075718, "Phase 2/Phase 3 Trial to Evaluate the Safety and Efficacy of the Second Generation Travoprost Intracameral Implant". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07075718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*